학술논문
Phase I Study of S-Trans, Trans-Farnesylthiosalicylic Acid (Salirasib), a Novel Oral RAS Inhibitor in Patients With Refractory Hematologic Malignancies
Document Type
Article
Author
Source
In Clinical Lymphoma Myeloma and Leukemia July 2015 15(7):433-438
Subject
Language
ISSN
2152-2650